The federal government poured billions of dollars into domestic manufacturing in multiple sectors this year, and drug manufacturing was no different.
In the private sector, drugmakers like Catalent capitalized on the growth in popularity of weight-loss drugs like Wegovy with new production investments. Others expanded manufacturing capacity in areas such as cell therapy.
2023 also had a record-high amount of drug shortages in the U.S., affecting generic drugs like amoxicillin and ibuprofen, as well as cancer treatment drugs and ADHD pills.
As the year comes to a close, Manufacturing Dive rounded up some of the top drug manufacturing news of the past 12 months, highlighting the growth of some of the biggest drug manufacturing companies in the world.